Beckman Coulter Stock Gain Aided By Merger Activity In Diagnostics – Index
This article was originally published in The Gray Sheet
Executive Summary
Clinical diagnostics firm Beckman Coulter's stock is benefiting from recent merger activity among its rivals in the field and speculation that it too could become an acquisition target; shares advanced 14% in the third quarter to close at $73.76